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Background: C-type natriuretic peptide (CNP) has anti-inflammatory, anti-proliferative, and anti-migratory
properties. During the past years, CNP has attained an increasing interest by many research groups, especially in the
cardiovascular field. Nevertheless, still no reliable data exist on the difference of CNP concentration between serum
and plasma samples. Also, the influence of delayed blood sample proceeding is unknown. The aim of this study
was to investigate the difference of CNP and NT-proCNP concentrations between serum and plasma samples. In
order to identify potential methodological bias, this study should also validate the stability of CNP and NT-proCNP
in full blood samples stored at room temperature.
Findings: Triplets (serum, plasma, full blood) of fasting blood samples from 12 healthy male individuals were
collected. Analysis of CNP and NT-proCNP concentration was performed immediately following sampling, and after
30 minutes or 2 hours of storage at room temperature. Mean serum concentrations at baseline were 0.997 ±
0.379 ng/ml for CNP and 58.5 ± 28.3 pg/ml for NT-proCNP. Furthermore, NT-proCNP concentration did not change
significantly during the allotted time and did not differ between serum, plasma, and full blood samples. At baseline,
concentrations of CNP were significantly different between samples containing either sodium-citrate or EDTA as a
clotting inhibitor (1.933 ± 0.699 ng/ml vs. 0.991 ± 0.489 ng/ml, p = 0.001).
Conclusions: CNP and NT-proCNP are stable for at least two hours, even when sample processing is delayed or
blood probes are stored at room temperature. NT-proCNP assay demonstrated more consistent and reliable data
and should therefore be preferred for usage in clinical applications. Nevertheless, as recommended for ANP and
BNP, immunoassays for CNP should also be standardized or harmonized in the future.
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Introduction
C-type natriuretic peptide (CNP), identified in 1990 by
Sudoh et al., is the most ancient member of the natri-
uretic peptide family [1]. CNP selectively stimulates the
human natriuretic peptide receptor 2 (NPR2), which ac-
tivates the cGMP-dependent kinase (cGK) by elevating
intracellular concentration of cGMP [2]. In addition,
CNP binds NPR3 and in turn deactivates protein kinase A
by Gi-protein dependent inhibition of adenylate cyclase [3].
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reproduction in any medium, provided the or[4] and was also identified as an endothelium derived
relaxing factor [5]. Furthermore, CNP inhibits neointimal
restenosis, reduces vascular constrictive remodeling and
cardiac ischemia-reperfusion injury [6,7]. CNP plays an im-
portant role in bone growth, reproduction, nerve growth,
re-endothelialisation, as well as renal, pancreatic, and car-
diac function [2,3]. In addition, CNP has recently been
recognised to be involved in the development of athero-
sclerotic plaque formation [8,9].
Due to the plethora of CNP functions, this peptide has
attained increasing interest in cardiovascular research
during the past years. However, studies concerning CNP
concentrations in blood samples are inconsistent. Some
of these studies measured concentrations of CNP or its
amino-terminal pro-peptide (NT-proCNP) in serumLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tunately, details on potential delays during blood sam-
pling and subsequent sample processing have not yet
been reported. In the available literature thus far, no data
exist on the difference of CNP/NT-proCNP concentra-
tions between serum and plasma samples. Also, theTable 1 Overview of the reported baseline blood concentratio
Author, year Age n Subgroup
Del Ry, 2012 [11] 0-3d 41 newborns
4-30d 24 newborns
1-12 m 22 infants
1-12 32 childrens
64 ± 1 32 healthy adults
Del Ry, 2011 [10] 64 ± 1 130 heart failure
63 ± 2 19 diabetes
52 ± 1 24 liver cirrhosis
61 ± 2 73 healthy
Olewicz-Gawlik, 2010 [17] 60 ± 15 40 RA
30 healthy
Vlachopoulos, 2009 [21] 57 ± 10 52 erectile dysfunctio
matched 31 healthy
Palmer, 2009 [19] 64 ± 9 120 cardiovascular disea
Dietmann, 2008 [14] 0.8-3.6 50 Malaria, severe
0.8-2.0 39 Malaria, uncomplicated
250.8-6.4
Yagci, 2008 [22] 34 ± 6 26 healthy
34 ± 9 28 Behcet, active
25 Behcet, inactive
Del Ry, 2007 [12] 62 ± 2 51 ILVD
61 ± 2 60 healthy
Olney, 2007 [18] 13 ± 2 10 GHD baseline
GHD under therap
14 ± 1 11 healthy
Lupattelli, 2006 [16] 35-60 44 Hyperlipidemia
matched 20 healthy controls
Del Ry, 2005 [13] 61 ± 2 21 healthy
Prickett, 2001 [20] 33 - 91 22 heart failure
25 - 55 16 healthy
Gülberg, 2000 [15] 57 ± 2 20 liver cirrhosis, RI
52 ± 2 20 liver cirrhosis, no R
45 ± 6 11 healthy
present study 29 ± 2 12 healthy
At baseline, CNP concentrations are measured in blood samples anticoagulated eith
either with RIA-assay (R) or ELISA-assay (E). Unless otherwise indicated (d = days, m
cardiovascular risk factors, RA = rheumatoid arthritis, ILVD = idiopathic left ventricleinfluence of the delay of blood sample processing re-
mains unclear. In addition, CNP concentration in serum
and plasma samples varied markedly (Table 1). There-
fore, the aim of this study was to answer the following
methodological questions: (1) Does delayed processing
of the blood samples stored at room temperature causens of CNP and NT-proCNP (mean ± SD)
CNP (pg/ml) NT-proCNP (pg/ml)






7.86 ± 0.41*R 67.1 ± 7.36
8.70 ± 1.62*R 51.5 ± 5.75
4.97 ± 0.55*R 78.4 ± 19.9
2.35 ± 0.11*R 45.5 ± 1.84
105 ± 189
50 ± 35




















I 3.0 ± 0.2*R
4.2 ± 0.4*R
997 ± 379E 991 ± 489*E 58.5 ± 28.3 60.3 ± 23.9
1933 ± 699°E
er with EDTA(*) or sodium-citrate (°). Concentration of CNP was measured
= months), age is given in years. a = arterial blood sample, CVRF =
dysfunction, RI = renal insufficiency, GHD = growth hormone deficiency.
Figure 1 Concentrations of CNP and NT-proCNP in blood samples.
a) Concentration of CNP in serum, plasma and full blood samples
(means, 95% confidence intervals). CNP concentrations in plasma
samples are significantly higher compared to serum and full blood
samples at all time points (ANOVA, p = 0.001 at baseline, p < 0.001 at 30’
and p = 0.003 at 120’). There is no significant difference between
serum and full blood samples at any time point (ANOVA, p > 0.05).
b) Concentration of NT-proCNP in serum, plasma and full blood
samples (means, 95% confidence intervals). There is no significant
difference between the groups at any time point (ANOVA, p > 0.05).
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plasma concentrations of CNP or NT-proCNP? (3) Are
these differences time dependent?
Methods
We studied 12 male volunteers (mean age 29 ± 2 years,
normal weight, no drug therapy, no history of cardiovas-
cular or other diseases, 3 smokers). From all investigated
subjects informed consent was obtained. Triplets of
fasting blood samples were taken from all volunteers at
8 o’clock in the morning. Blood samples were collected
using the 7.5 ml S-MonovetteW collection system
(Sarstedt, Nümbrecht, Germany) containing either clot-
ting activator (Kaolin) for serum samples, sodium-citrate
for plasma samples or Potassium–EDTA for full blood
samples. All samples for baseline analyses were immedi-
ately centrifuged at 2,000 × g for 10 min at 4°C and
supernatant was stored at −70°C until analysis. For mid-
term analyses (30 minutes or 2 hours), plasma samples
were centrifuged at 2,000 × g for 10 min at room
temperature. Supernatant was removed and stored at
room temperature for 30 min or 2 hours. Following
blood clotting, serum samples were processed identically
to plasma samples. Supernatant was saved and also
stored at room temperature for 30 min or 2 hours. Full
blood samples were stored at room temperature without
centrifugation. After 30 min or 2 hours, full blood sam-
ples were centrifuged at 2,000 × g for 10 min at 4°C.
Supernatant was removed and stored at −70°C until ana-
lysis. The concentration of CNP was measured using the
CNP-22 EIA Kit (#EK-012-03, Phoenix Pharmaceuticals,
Karlsruhe, Germany) according to the manufacturer’s
protocol. NT-proCNP concentration was measured
using the NT-proCNP EIA Kit (Biomedica, Vienna,
Austria) according to the manufacturer’s protocol.
One-way ANOVA was used for comparison between
groups. For pairwise comparisons, the t-test was applied.
Data are shown as means ± standard deviation (SD) or
95% confidence interval (95%-CI). Statistical significance
was assumed at p < 0.05. Data were analyzed using
MedCalcW for Windows, Version 10.0.1.0 (MedCalc
Software, Mariakerke, Belgium).
Results
As shown in Figure 1a, baseline concentrations of CNP in
serum, plasma, and full blood samples were 0.997 ±
0.379 ng/ml, 1.933 ± 0.699 ng/ml, and 0.991 ± 0.489 ng/ml,
respectively. Plasma concentrations of CNP were signifi-
cantly higher compared to serum and full blood samples at
all time points (ANOVA, p = 0.001 at baseline, p < 0.001 at
30’ min. and p = 0.003 at 120’ min.). No significant differ-
ence was observed between serum and full blood samples
at any time point (ANOVA, p > 0.05). Baseline concentra-
tions of NT-proCNP in serum, plasma, and full bloodsamples were 58.5 ± 28.3 pg/ml, 60.3 ± 23.9 pg/ml, and
50.7 ± 21.4 pg/ml, respectively (Figure 1b). No significant
difference was found between the groups at any time point
(ANOVA, p > 0.05). In full blood samples, concentration of
lactate increased significantly after 2 hours compared to
baseline value (3.2 ± 0.8 mM vs. 2.0 ± 0.6 mM, p < 0.001).
In addition, pH-value decreased from 7.34 ± 0.03 at base-
line to 7.29 ± 0.03 after 2 hours (p < 0.001).
Discussion
Our study revealed that CNP and NT-proCNP are stable
in serum and in full blood samples for at least two hours at
room temperature. Consequently, the stability of the CNP
peptide is most likely not affected by any delay in sample
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reported (manufacturer’s protocol, unknown storage
conditions of blood samples) to be stable for at least
2.5 hours. Accordingly, our experiments confirmed the sta-
bility of NT-proCNP even at room temperature. The con-
centration of NT-proCNP in all sample types remained
constant during the time course for up to 2 hours, indicat-
ing long lasting stability of this protein. As listed in Table 1,
the mean concentration of NT-proCNP (56.5 ± 24.3 pg/ml)
measured in this study was within the reported range
(see Table 1) of healthy individuals (3.7-432 pg/ml).
In contrast to NT-proCNP, the concentration of CNP
was significantly higher in plasma samples compared to
serum and full blood samples (Figure 1). So far, neither
our group nor manufacturers technical service found
any evidence concerning the influence of sample type on
the ELISA assay used in this study. However, at baseline,
supernatant of plasma and full blood samples were iden-
tical with the exception of type of blood clotting inhibi-
tor used. This inhibitor was sodium citrate in the plasma
group and EDTA in the full blood sample group. Full
blood samples revealed comparable results to serum
samples (p = 0.98). Therefore, it is most likely that so-
dium citrate may significantly influence the measured
concentration of CNP in plasma and consequently falsify
the results achieved by this technique.
Unexpectedly, baseline concentrations of CNP in both
plasma and serum samples were about a thousand-fold
higher than in other reports (Table 1) [10-13,15,19]. In all
of these studies the Radioimmunoassay (RIA-Kit) was
used for the determination of CNP concentrations. In
contrast, in two other studies the measured CNP concen-
trations in serum and plasma samples were comparable to
our results with respect to the magnitude of dimension
[16,22]. Interestingly, in the latter studies, the same
ELISA-Kit was used as in our investigation. Even after ex-
tensive evaluation of various internal and external factors,
no satisfied explanation of this discrepancy could be
found. Control measurements using exogenous CNP in
human serum revealed a non-significant measurement
error of +7.8% (95%-KI: [−1.9%]–[+17.5%]). The CNP
peptide used for the reference curve was synthesized by
the manufacturer itself (Phoenix). In contrast, the CNP
peptide used as the “exogenous” control was provided by
Bachem. As assured by both manufacturers, sequences of
amino acids were identical and disulfide bonds were
formed in both peptides.
However, results of internal control measurements can
be summarised as follows: First, the control measurements
performed in our study revealed that the ELISA kits were
used properly, in accordance with the manufacturer’s in-
structions. Second, measurements using control samples
confirmed suitability of standard curve applied. Third, con-
trol serum samples containing exogenous CNP revealedacceptable accuracy and results were within the expected
order of magnitude. Fourth, a higher concentration of
CNP in plasma samples is most likely an artefact caused by
sodium-citrate.
As reported by Clerico and co-workers, comparably
great differences in results among different RIA and EIA
methods are also known for, e.g. ANP and BNP [23-26].
Clerico and co-workers concluded that the large differ-
ences in these results are most likely due to the specificity
of monoclonal or polyclonal antibodies used, the design of
immunoassay system (competitive vs. non-competitive
assay), the analytical matrix (serum vs. EDTA vs. heparin-
ized plasma) used, and the plethora of circulating forms of
natriuretic peptides, as previously reported for ANP and
BNP immunoassays [23,26,27]. These methodological
sources of bias may also be conceivable for CNP and
NT-proCNP assays and thus explain the great difference
in results in the cited studies (Table 1).
Limitations of the study
We acknowledge that a sample size of 12 is too small to
conclude that there is no difference at all. However, from
a statistical point of view, it would be important to spe-
cify how large the difference must be to be of medical
relevance. To our knowledge, the latter is not yet clearly
defined. Therefore, the means and 95%-confidence inter-
vals of all measures were given in the figure to enable
every reader to draw his own interpretation from the
data as well.
In reference to serum and plasma concentrations, it
must be mentioned that the values reported in Table 1
were measured with different methods (RIA, ELISA) in pa-
tients suffering from different diseases. It would have been
very helpful to compare CNP-RIA with CNP-ELISA assays
directly using the same specimens, because a thousand-
fold difference in the order of magnitude remains notice-
able. Unfortunately, RIA assays measurements were not
available in our laboratory. For NT-proCNP concentration,
the latter comparison was investigated by Olney and
co-workers[28] showing that the commercial ELISA
(Biomedica Medizinprodukte GmbH & Co KG, Vienna,
Austria) gave values that were an average of 21% (range
11-52%) of the RIA values. Cross-validation of the refer-
ence standard of the ELISA kit using RIA assay showed a
disagreement of 15% [28].
Summary
Measurements of CNP and NT-proCNP were most likely
unaffected by delay of sample procession or type of blood
sample (except for CNP in plasma samples). For plasma
samples, only EDTA anticoagulated blood samples were
suitable for the CNP ELISA assay used in this study. Con-
sequently, the concentration of CNP and NT-proCNP
could be used in clinical applications in order to determine
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tration of NT-proCNP, being only a by-product of the ac-
tive peptide, may conceal the true nature of CNP.
However, discrepancy in measured CNP concentrations
determined either by RIA-assays or by ELISA-assays still
remains unexplained but seems most likely to be due to
methodological issues. Therefore, as recommended for
ANP and BNP [23], immunoassays for CNP need also to
be standardized or harmonized in the future.
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